Eosinophilic Esophagitis Treatment for Patients

For your patients aged 12 years and older, weighing
at least 40 kg,
with eosinophilic esophagitis (EoE).

THE FIRST AND ONLY FDA-APPROVED EoE TREATMENT

TRANSFORM THE WAY
YOU MANAGE EoE

Discover clinical, histologic,
and
endoscopic results^1-3

DATA UP TO 52 WEEKS
is available

Clinical, histologic, and
endoscopic endpoints^1,2

DUPIXENT was studied across
multiple endpoints.

VIEW THE RESULTS

Demonstrated
safety profile¹

The safety of DUPIXENT was
evaluated
at Week 24 and up
to 52 weeks in the
multipart,
phase 3 clinical trial.

EXPLORE THE DATA

DUPIXENT MyWay® is a patient support
program
that can help
enable access to
DUPIXENT
and offers financial assistance
for
eligible
patients, one-on-one nursing
support, and more.

LEARN HOW WE CAN HELP

*DUPIXENT MyWay* ENROLLMENT FORMS
English Enrollment Form
Spanish Enrollment Form

Contact a Field
Representative

Connect with a DUPIXENT Field Representative to get answers to your product-related questions.

CONTACT A REP

THE FIRST AND ONLY FDA-APPROVED EoE TREATMENT

Clinical, histologic, and endoscopic endpoints1,2

DUPIXENT was studied across multiple endpoints.

Demonstrated safety profile1

The safety of DUPIXENT was evaluated at Week 24 and up to 52 weeks in the multipart, phase 3 clinical trial.

DUPIXENT MyWay ENROLLMENT FORMS

Are you sure you want to leave?

Are you sure you want to leave?

Clinical, histologic, and
endoscopic endpoints^1,2

DUPIXENT was studied across
multiple endpoints.

Demonstrated
safety profile¹

The safety of DUPIXENT was
evaluated
at Week 24 and up
to 52 weeks in the
multipart,
phase 3 clinical trial.

DUPIXENT MyWay
ENROLLMENT FORMS